146 related articles for article (PubMed ID: 27256394)
1. Duration of Viral Suppression and Risk of Rebound Viremia with First-Line Antiretroviral Therapy in Rural Uganda.
Musinguzi N; Mocello RA; Boum Y; Hunt PW; Martin JN; Haberer JE; Bangsberg DR; Siedner MJ
AIDS Behav; 2017 Jun; 21(6):1735-1740. PubMed ID: 27256394
[TBL] [Abstract][Full Text] [Related]
2. Duration of Antiretroviral Therapy Adherence Interruption Is Associated With Risk of Virologic Rebound as Determined by Real-Time Adherence Monitoring in Rural Uganda.
Haberer JE; Musinguzi N; Boum Y; Siedner MJ; Mocello AR; Hunt PW; Martin JN; Bangsberg DR
J Acquir Immune Defic Syndr; 2015 Dec; 70(4):386-92. PubMed ID: 26110445
[TBL] [Abstract][Full Text] [Related]
3. Younger Age Predicts Failure to Achieve Viral Suppression and Virologic Rebound Among HIV-1-Infected Persons in Serodiscordant Partnerships.
Mujugira A; Celum C; Tappero JW; Ronald A; Mugo N; Baeten JM
AIDS Res Hum Retroviruses; 2016 Feb; 32(2):148-54. PubMed ID: 26670218
[TBL] [Abstract][Full Text] [Related]
4. Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level.
Lima VD; Bangsberg DR; Harrigan PR; Deeks SG; Yip B; Hogg RS; Montaner JS
J Acquir Immune Defic Syndr; 2010 Dec; 55(4):460-5. PubMed ID: 20838225
[TBL] [Abstract][Full Text] [Related]
5. A simple self-reported adherence tool as a predictor of viral rebound in people with viral suppression on antiretroviral therapy.
O'Connor JL; Gardner EM; Esser S; Mannheimer SB; Lifson AR; Telzak EE; Phillips AN;
HIV Med; 2016 Feb; 17(2):124-32. PubMed ID: 26186609
[TBL] [Abstract][Full Text] [Related]
6. Examining adherence barriers among women with HIV to tailor outreach for long-acting injectable antiretroviral therapy.
Benning L; Mantsios A; Kerrigan D; Coleman JS; Golub E; Blackstock O; Konkle-Parker D; Philbin M; Sheth A; Adimora AA; Cohen MH; Seidman D; Milam J; Kassaye SG; Taylor T; Murray M
BMC Womens Health; 2020 Jul; 20(1):152. PubMed ID: 32711509
[TBL] [Abstract][Full Text] [Related]
7. Health Care-Specific Enacted HIV-Related Stigma's Association with Antiretroviral Therapy Adherence and Viral Suppression Among People Living with HIV in Florida.
Algarin AB; Sheehan DM; Varas-Diaz N; Fennie KP; Zhou Z; Spencer EC; Cook RL; Morano JP; Ibanez GE
AIDS Patient Care STDS; 2020 Jul; 34(7):316-326. PubMed ID: 32639208
[TBL] [Abstract][Full Text] [Related]
8. Brief Report: Appraising Viral Load Thresholds and Adherence Support Recommendations in the World Health Organization Guidelines for Detection and Management of Virologic Failure.
McCluskey SM; Boum Y; Musinguzi N; Haberer JE; Martin JN; Hunt PW; Marconi VC; Bangsberg DR; Siedner MJ
J Acquir Immune Defic Syndr; 2017 Oct; 76(2):183-187. PubMed ID: 28628529
[TBL] [Abstract][Full Text] [Related]
9. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
[TBL] [Abstract][Full Text] [Related]
10. Incomplete adherence to antiretroviral therapy is associated with higher levels of residual HIV-1 viremia.
Li JZ; Gallien S; Ribaudo H; Heisey A; Bangsberg DR; Kuritzkes DR
AIDS; 2014 Jan; 28(2):181-186. PubMed ID: 24361679
[TBL] [Abstract][Full Text] [Related]
11. Secret intake of antiretroviral treatment and HIV-1 viremia in a public routine clinic in Burkina Faso: a surprising relationship.
Penot P; Héma A; Bado G; Sombié D; Kaboré FN; Poda A; Michon C; Terzolo O; Traoré A; Slama L; Sawadogo A; Laurent C
AIDS Care; 2018 Dec; 30(12):1502-1506. PubMed ID: 29991274
[TBL] [Abstract][Full Text] [Related]
12. Incidences and factors associated with viral suppression or rebound among HIV patients on combination antiretroviral therapy from three counties in Kenya.
Maina EK; Mureithi H; Adan AA; Muriuki J; Lwembe RM; Bukusi EA
Int J Infect Dis; 2020 Aug; 97():151-158. PubMed ID: 32497804
[TBL] [Abstract][Full Text] [Related]
13. Durable Suppression of HIV-1 after Virologic Monitoring-Based Antiretroviral Adherence Counseling in Rakai, Uganda.
Billioux A; Nakigozi G; Newell K; Chang LW; Quinn TC; Gray RH; Ndyanabo A; Galiwango R; Kiggundu V; Serwadda D; Reynolds SJ
PLoS One; 2015; 10(5):e0127235. PubMed ID: 26011158
[TBL] [Abstract][Full Text] [Related]
14. HIV viral suppression and risk of viral rebound in patients on antiretroviral therapy: a two- year retrospective cohort study in Northern Tanzania.
Kahabuka MS; Woldeamanuel Y; Mbelele PM; Mpolya EA; Mpagama SG; Kessy JP; Manyazewal T
BMC Infect Dis; 2024 Apr; 24(1):390. PubMed ID: 38605325
[TBL] [Abstract][Full Text] [Related]
15. The relative contributions of HIV drug resistance, nonadherence and low-level viremia to viremic episodes on antiretroviral therapy in sub-Saharan Africa.
Inzaule SC; Bertagnolio S; Kityo CM; Siwale M; Akanmu S; Wellington M; de Jager M; Ive P; Mandaliya K; Stevens W; Boender TS; Ondoa P; Sigaloff KCE; Rinke de Wit TF; Hamers RL
AIDS; 2020 Aug; 34(10):1559-1566. PubMed ID: 32675566
[TBL] [Abstract][Full Text] [Related]
16. Antiretroviral therapy initiation within seven days of enrolment: outcomes and time to undetectable viral load among children at an urban HIV clinic in Uganda.
Ssebunya R; Wanyenze RK; Lukolyo H; Mutto M; Kisitu G; Amuge P; Maganda A; Kekitiinwa A
BMC Infect Dis; 2017 Jun; 17(1):439. PubMed ID: 28629459
[TBL] [Abstract][Full Text] [Related]
17. Use of a prescription-based measure of antiretroviral therapy adherence to predict viral rebound in HIV-infected individuals with viral suppression.
Cambiano V; Lampe FC; Rodger AJ; Smith CJ; Geretti AM; Lodwick RK; Holloway J; Johnson M; Phillips AN
HIV Med; 2010 Mar; 11(3):216-24. PubMed ID: 20002781
[TBL] [Abstract][Full Text] [Related]
18. Incidence of Health Facility Switching and Associations With HIV Viral Rebound Among Persons on Antiretroviral Therapy in Uganda: A Population-based Study.
Rosen JG; Ndyanabo A; Nakawooya H; Galiwango RM; Ssekubugu R; Ssekasanvu J; Kim S; Rucinski KB; Nakigozi G; Nalugoda F; Kigozi G; Quinn TC; Chang LW; Kennedy CE; Reynolds SJ; Kagaayi J; Grabowski MK
Clin Infect Dis; 2024 Jun; 78(6):1591-1600. PubMed ID: 38114162
[TBL] [Abstract][Full Text] [Related]
19. Improved virological suppression in children on antiretroviral treatment receiving community-based adherence support: a multicentre cohort study from South Africa.
Fatti G; Shaikh N; Eley B; Grimwood A
AIDS Care; 2014 Apr; 26(4):448-53. PubMed ID: 24215157
[TBL] [Abstract][Full Text] [Related]
20. Rethinking the "pre" in pre-therapy counseling: no benefit of additional visits prior to therapy on adherence or viremia in Ugandans initiating ARVs.
Siedner MJ; Lankowski A; Haberer JE; Kembabazi A; Emenyonu N; Tsai AC; Muzoora C; Geng E; Martin JN; Bangsberg DR
PLoS One; 2012; 7(6):e39894. PubMed ID: 22761924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
